Perrigo Co (Allegan, MI)
Olux Foam (Connectics Corp.
March 20, 2008?Perrigo Co announced the launch of Clobetasol Propionate Foam. The US District Court for the District of New Jersey denied Connetics Corporation?s motion for a preliminary injunction related to Perrigo?s Clobetasol Propionate Foam and lifted the temporary restraints that prevented Perrigo?s launch. As the first company to file, Perrigo receives 180-day generic exclusivity. Clobetasol Propionate Foam is a topical corticosteroid indicated for the treatment of moderate-to-severe dermatitis of the scalp.
0.05% Foam in 50- and 100-mg cans
For More Information:
Teva Pharmaceuticals (North Wales, PA)
Grifulvin V (Johnson & Johnson Corp)
February 12, 2008?Teva Pharmaceuticals announced the introduction and availability of Griseofulvin Oral Suspension USP. Major indications for griseofulvin include: tinea capitis (ringworm of the scalp), tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea unguium (ringworm of the nails), tinea cruris (ringworm of the thigh), and tinea barbae (barber?s itch). Griseofulvin acts systemically to inhibit the growth of the Trichophyton, Microsporum, and Epidermophyton genera of fungi.
Paddock Laboratories (Minneapolis, MN)
Neomycin and Polymyxin B Sulfates and Gramicidin Ophthalmic Solution, USP (Bausch and Lomb)
January 2, 2008?Paddock Laboratories announced the availability of Neomycin and Polymyxin B Sulfates and Gramicidin Ophthalmic Solution, USP. The solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa, such as conjunctivitis, keratitis, blepharitis, etc, caused by susceptible bacteria.
ETHEX Corp (St. Louis, MO)
April 3, 2008?ETHEX Corp announced the introduction of 2 new strengths of immediate-release Oxycodone HCl Tablets?10 and 20 mg. The new 10- and 20-mg strengths are designed to bridge the gap between existing oxycodone HCl strengths, providing prescribers and patients with greater dosing flexibility. ETHEX is the only company to offer immediate-release oxycodone HCl tablets in 5 strengths: 5, 10, 15, 20, and 30 mg. These tablets are indicated for the relief of moderate-to-severe pain where the use of an opioid analgesic is appropriate.
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs